Search Clinical Trials
583,492 trials
ID
Status
Phase
Title
Sponsor
NCT07574320
Effect of Ramosetron in Patients With Diarrhea Predominant Irritable Bowel SyndromeMd. Aminul IslamNot Yet RecruitingPhase 4
NCT07574320Not Yet Recruiting
Phase 4
Effect of Ramosetron in Patients With Diarrhea Predominant Irritable Bowel Syndr...Md. Aminul Islam
NCT07573813
Novel SaCoVLM™ Video Laryngeal Mask Airway as an Intubation Conduit in Morbidly Obese Bariatric SurgeryYongtao SunCompleted
NCT07573813Completed
—
Novel SaCoVLM™ Video Laryngeal Mask Airway as an Intubation Conduit in Morbidly...Yongtao Sun
NCT07572357
Clinical Evaluation of the RH210 Hearing AidGlobal Edge Medtech ConsultingNot Yet RecruitingNot Applicable
NCT07572357Not Yet Recruiting
Not Applicable
Clinical Evaluation of the RH210 Hearing AidGlobal Edge Medtech Consu...
NCT07573202
Silk Fibroin Versus 2-octyl Cyanoacrylate Mesh a Randomized Controlled Trial to Evaluate Hypersensitivity Reactions in Shoulder SurgeryThe University of Texas Health Science Center, HoustonNot Yet RecruitingNot Applicable
NCT07573202Not Yet Recruiting
Not Applicable
Silk Fibroin Versus 2-octyl Cyanoacrylate Mesh a Randomized Controlled Trial to...The University of Texas H...
NCT07572747
Aspirin Versus Clopidogrel in Chronic Coronary Syndrome in Arabian Gulf CountriesKhalid F AlhabibNot Yet RecruitingPhase 3
NCT07572747Not Yet Recruiting
Phase 3
Aspirin Versus Clopidogrel in Chronic Coronary Syndrome in Arabian Gulf Countrie...Khalid F Alhabib
NCT07574424
Normative Values For Physical FitnessRiphah International UniversityEnrolling By Invitation
NCT07574424Enrolling By Invitation
—
Normative Values For Physical FitnessRiphah International Univ...
NCT07572136
Phase I Dose Escalation Study of Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-cell Acute Lymphoblastic Leukemia (B-ALL)National Cancer Institute (NCI)Not Yet RecruitingPhase 1
NCT07572136Not Yet Recruiting
Phase 1
Phase I Dose Escalation Study of Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T...National Cancer Institute...
NCT07573124
Efficacy of Combining Mulligan Spinal Mobilization With Leg Movement and Mechanical Lumbar Traction in Lumbar RadiculopathyKhyber Medical University PeshawarRecruitingNot Applicable
NCT07573124Recruiting
Not Applicable
Efficacy of Combining Mulligan Spinal Mobilization With Leg Movement and Mechani...Khyber Medical University...
NCT07573241
Single Arm Trial Identifying Barriers and Facilitators to Mindfulness PracticeNational Center for Complementary and Integrative Health (NCCIH)Not Yet RecruitingNot Applicable
NCT07573241Not Yet Recruiting
Not Applicable
Single Arm Trial Identifying Barriers and Facilitators to Mindfulness PracticeNational Center for Compl...
NCT07572305
Effects of Virtual Reality After Liver TransplantationMalatya Turgut Ozal UniversityCompletedNot Applicable
NCT07572305Completed
Not Applicable
Effects of Virtual Reality After Liver TransplantationMalatya Turgut Ozal Unive...
NCT07573722
Neck Exercises for Improving Pelvic Alignment and Low Back PainYuanpei University of Medical TechnologyCompletedNot Applicable
NCT07573722Completed
Not Applicable
Neck Exercises for Improving Pelvic Alignment and Low Back PainYuanpei University of Med...
NCT07574242
Effect of vitk2 on Atopic Dermatitis Pediatrics PatientsOctober 6 UniversityCompletedNot Applicable
NCT07574242Completed
Not Applicable
Effect of vitk2 on Atopic Dermatitis Pediatrics PatientsOctober 6 University
NCT07572097
High-Frequency Irreversible Electroporation vs Standard of Care for Benign Prostatic HyperplasiaShanghai East HospitalNot Yet RecruitingNot Applicable
NCT07572097Not Yet Recruiting
Not Applicable
High-Frequency Irreversible Electroporation vs Standard of Care for Benign Prost...Shanghai East Hospital
NCT07572214
Markerless Motion Capture for 3D Clinical Gait Analysis (IMAGine)Alder Hey Children's NHS Foundation TrustCompleted
NCT07572214Completed
—
Markerless Motion Capture for 3D Clinical Gait Analysis (IMAGine)Alder Hey Children's NHS...
NCT07573059
Evaluation of the Safety of Loargys Arginine Test System in Loargys-treated PatientsImmedica Pharma US IncRecruitingNot Applicable
NCT07573059Recruiting
Not Applicable
Evaluation of the Safety of Loargys Arginine Test System in Loargys-treated Pati...Immedica Pharma US Inc
NCT07573748
Apple Vision Pro-Assisted Vascular Identification in Lung SurgeryThe Second People's Hospital of Huai'anNot Yet RecruitingNot Applicable
NCT07573748Not Yet Recruiting
Not Applicable
Apple Vision Pro-Assisted Vascular Identification in Lung SurgeryThe Second People's Hospi...
NCT07572435
Preliminary Efficacy of a Remote Cardiac Rehabilitation Program in Pediatric Patients With Complex Congenital Heart DiseaseSeoul National University HospitalRecruitingNot Applicable
NCT07572435Recruiting
Not Applicable
Preliminary Efficacy of a Remote Cardiac Rehabilitation Program in Pediatric Pat...Seoul National University...
NCT07572045
Promoting Interventions for Climate Change to Upscale Resilience in District BadinDr Jai Kumar DasNot Yet RecruitingNot Applicable
NCT07572045Not Yet Recruiting
Not Applicable
Promoting Interventions for Climate Change to Upscale Resilience in District Bad...Dr Jai Kumar Das
NCT07573020
Influence of Acellular Dermal Matrix on Peri-implant Soft Tissue Phenotype and Marginal Bone LossMansoura UniversityCompletedNot Applicable
NCT07573020Completed
Not Applicable
Influence of Acellular Dermal Matrix on Peri-implant Soft Tissue Phenotype and M...Mansoura University
NCT07573631
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular DystrophyBioMarin PharmaceuticalEnrolling By InvitationPhase 2
NCT07573631Enrolling By Invitation
Phase 2
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of B...BioMarin Pharmaceutical
Result Breakdown
Not yet recruiting9 (45%)
Completed6 (30%)
Recruiting3 (15%)
Enrolling by invitation2 (10%)
not_applicable13 (65%)
Not Specified3 (15%)
Phase 41 (5%)
Phase 31 (5%)
Phase 11 (5%)
Phase 21 (5%)